SCHEMBL27378973

SCHEMBL27378973

Cc1cccc(C2CCC(F)(F)CC2)c1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ HDAC4 P56524 1/20 0.36
▸ HTR2C P28335 4/20 0.36
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35
▸ TAS1R2 Q8TE23 1/20 0.35
▸ IDH1 O75874 1/20 0.34
▸ IDH2 P48735 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ PLAT P00750 1/20 0.33
▸ GRM6 O15303 1/20 0.33
▸ CCR5 P51681 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ IL1B P01584 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27375885 0.88 CA12 (0.37) MEN1KMT2AATMIDH1IDH2
SCHEMBL27375857 0.88 MEN1 (0.36) MEN1KMT2AATMHDAC4IDH1
SCHEMBL30755212 0.88 CA12 (0.37) MEN1KMT2AATMIDH1IDH2
SCHEMBL27374381 0.85 MEN1 (0.35) MEN1KMT2AATMIDH1IDH2
SCHEMBL30755433 0.84 HDAC4 (0.36) MEN1KMT2AATMHDAC4IDH1
SCHEMBL27379299 0.84 HDAC4 (0.36) MEN1KMT2AATMHDAC4IDH1
SCHEMBL27379394 0.83 HSD11B1 (0.39) MEN1KMT2AATMIL1BP2RX7
SCHEMBL27372125 0.82 HTR2C (0.36) MEN1KMT2AATMHTR2CTAS1R3
SCHEMBL30755472 0.82 IDH1 (0.35) MEN1KMT2AATMIDH1IDH2
SCHEMBL27362604 0.82 SLC6A2 (0.33) MEN1KMT2AATMIDH1IDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
EP-4562016-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 MEN1 3868/4885KMT2A 607/4885ATM 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback